Billiontoone (NASDAQ:BLLN) SVP Sells $141,700.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,417 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $100.00, for a total value of $141,700.00. Following the completion of the transaction, the senior vice president owned 26,467 shares of the company’s stock, valued at approximately $2,646,700. The trade was a 5.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total value of $131,582.62.
• On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00.
• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Stock Performance

BLLN opened at $93.24 on Friday. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $150.44. The firm has a 50 day moving average of $115.10 and a two-hundred day moving average of $95.27. The firm has a market capitalization of $4.40 billion and a PE ratio of 133.20.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million for the quarter. On average, analysts anticipate that Billiontoone, Inc. will post 0.83 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rossby Financial LCC acquired a new stake in shares of Billiontoone during the 4th quarter valued at about $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone in the 4th quarter worth about $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone in the 4th quarter worth about $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Billiontoone during the fourth quarter worth approximately $82,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Billiontoone during the fourth quarter worth approximately $230,000.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BLLN. BTIG Research cut their price target on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Guggenheim began coverage on Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. decreased their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a report on Thursday, August 6th. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $126.71.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.